Background: Coenzyme Q10 (CoQ10) supplementation is the most popular therapy for statin myalgia among both physicians and patients despite limited and conflicting evidence of its efficacy. Objective: This study examined the effect of coenzyme Q10 (CoQ10) supplementation on simvastatin-associated muscle pain, muscle strength and aerobic performance in patients with confirmed statin myalgia. Methods: Statin myalgia was confirmed in 120 patients with prior symptoms of statin myalgia using an 8-week randomized, double-blind crossover trial of simvastatin 20 mg/d and placebo. Forty-one subjects developed muscle pain with simvastatin but not with placebo and were randomized to simvastatin 20 mg/d combined with CoQ10 (600 mg/d ubiquinol) or placebo for 8 weeks. Muscle pain (Brief Pain Inventory [BPI]), time to pain onset, arm and leg muscle strength, and maximal oxygen uptake (VO2max) were measured before and after each treatment. Results: Serum CoQ10 increased from 1.3 ± 0.4 to 5.2 ± 2.3 mcg/mL with simvastatin and CoQ10, but did not increase with simvastatin and placebo (1.3 ± 0.3 to 0.8 ± 0.2) (p < 0.05). BPI pain severity and interference scores increased with simvastatin therapy (both p < 0.01), irrespective of CoQ10 assignment (p ¼ 0.53 and 0.56). There were no changes in muscle strength or VO2max with simvastatin with or without CoQ10 (all p > 0.10). Marginally more subjects reported pain with CoQ10 (14 of 20 vs 7 of 18; p ¼ 0.05). There was no difference in time to pain onset in the CoQ10 (3.0 ± 2.0 weeks) vs. placebo (2.4 ± 2.1 wks) groups (p ¼ 0.55). A similar lack of CoQ10 effect was observed in 24 subjects who were then crossed over to the alternative treatment. Conclusions: Only 36% of patients complaining of statin myalgia develop symptoms during a randomized, double-blind crossover of statin vs placebo. CoQ10 supplementation does not reduce muscle pain in patients with statin myalgia. Trial RegistrationNCT01140308; www.clinicaltrials.gov.
Introduction
Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins reduce low-density lipoprotein (LDL)-cholesterol concentrations and cardiac events [1] . Statins are welltolerated but can produce myalgia in 1e25% of patients [2e4] . In the Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study, we observed a doubling of muscle complaints from 4.6 to 9.4% of subjects among 420 subjects treated with high dose atorvastatin (80 mg/d) or placebo for 6 mos [3] .
How statins produce muscular side effects is not clear, but depletion of the mitochondrial transport element ubiquinone, or coenzyme Q10 (CoQ10), is a possible mechanism since CoQ10 is also produced by the cholesterol metabolic pathway [5] . The effects of CoQ10 supplementation on statin myalgia have not been extensively studied, and available studies are small and have produced conflicting results [6, 7] . Nevertheless, CoQ10 supplementation is used by many patients and recommended by many clinicians despite the absence of definitive results. A major limitation of prior studies is that statin myalgia was based on self-report. We designed the Co-Enzyme Q10 in Statin Myopathy study to evaluate the effect of CoQ10 supplementation in subjects whose muscle complaints were confirmed using a lead-in, double-blind, placebo comparison of statin vs placebo.
Methods
Confirmation of Statin-Associated Myalgia. Men and women !20 yrs of age with a history of muscle complaints during statin treatment were recruited from the Cholesterol Management Center at Hartford Hospital, newspaper and radio advertisements, and contact with physicians' offices. Subjects were excluded if they had cancer within 5 years of entry, hypo-or hyperthyroidism (TSH > 5 or <0.01 IU/L), hepatic disease (ALT > 2 UNL), renal disease (creatinine> 2 mg/dL) or were using medications (such as corticosteroids) known to affect skeletal muscle metabolism. Subjects using supplemental CoQ10 discontinued supplementation for 2 months before the study. As previously detailed [8] (Fig. 1) , subjects' cholesterol medications were discontinued for 4 weeks. Subjects then entered a randomized, double-blind, crossover, leadin trial of simvastatin (20 mg/d) or placebo to confirm statin myalgia. Subjects were treated for 8 weeks or until muscle symptoms persisted for 1 week or were intolerable. Subjects then underwent a 4-week wash-out period, and were crossed over from simvastatin to placebo or vice versa. Only subjects who experienced muscle pain on simvastatin but not on placebo and whose pain resolved within 4 weeks off treatment were entered into the CoQ10 Lipids: total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides. ALT ¼ alanine aminotransferase, CK ¼ creatine kinase, CK-MB ¼ creatine kinase heart-specific isoform, TSH ¼ thyroid-stimulating hormone.
trial.
Study pharmacists compounded identical simvastatin and placebo capsules and subjects were randomized in a 1:1 fashion according to www.randomization.com. Simvastatin tablets were obtained from a single supplier, cut, covered with lactose secundum artem, and placed into opaque capsules. Placebo tablets were filled with lactose alone. Muscle symptoms were documented weekly by telephone.
CoQ10 Treatment Study.Forty one subjects with confirmed statin myalgia (Fig. 2 ) entered another 4-week wash-out period and were then loaded for 2 weeks with either CoQ10 600 mg dailyor placebo to ensure adequate CoQ10 levels before simvastatin treatment. After loading, subjects were randomized by study pharmacists again using www.randomization.com to simvastatin 20 mg/ d and CoQ10 600 mg/d or simvastatin and placebo for 8 weeks or until muscle symptoms persisted for 1 week or were intolerable.
One of the CoQ10 and 2 of the placebo group subjects failed to complete the study because of unrelated changes in medical or personal circumstances that made them discontinue study treatment. A subset of subjects (n ¼ 24) who completed the study then entered another 4 week washout and crossed over from statin/ CoQ10 to statin/placebo or vice versa. The cross-over phase was added after some patients had completed the study because of the lower number of confirmed myalgics qualifying for the treatment phase; therefore only 24 of the 38 subjects who completed the first parallel treatment phase were crossed over to the alternative treatment. Pain intensity was recorded weekly, and subjects underwent phlebotomy as well as measurements of pain, muscle strength, VO2max, and physical activity level, at the beginning and end of each treatment phase.CoQ10 and placebo were obtained in identical matching 300 mg soft gelatin capsules from Tishcon Corporation (Waterbury, New York) according to standards for ubiquinol formation (CoQH2) delineated under the Investigational New Drug (IND) number assigned to the study (IND106208). All investigators and patients were blind to drug order and identity throughout the study. The study was approved by the Institutional Review Board at Hartford Hospital and a Data Safety and Monitoring Board (DSMB) composed of two physicians and a statistician oversaw the project with biannual meetings.
Serologic Markers. Creatinine and thyroid stimulating hormone (TSH) levels were measured before the lead-in trial. Blood was drawn at each testing point during the lead-in and CoQ10 section of the study for measurement of serum lipids (total, HDL, and LDL-cholesterol and triglycerides), creatine kinase (CK), vitamin D, and alanine aminotransferase (ALT) levels. Blood CoQ10 levels were measured as described [9] at the Children's Hospital Medical Center in Cincinnati, OH at each timepoint during both the myalgia confirmation phase and the CoQ10 trial.
Measurement of Muscle Pain. Subjects were contacted weekly during the confirmation and CoQ10 treatment portions of the study to inquire about muscle symptoms using the Brief Pain Inventory Short Form (BPI-SF) [10] .A pain severity score (PSS) was calculated by averaging scores on 4 pain-intensity items, and a pain interference score (PIS) was calculated by averaging scores on 7 paininterference items.
Muscle Strength and Endurance. Muscle strength and exercise performance were measured only during the treatment phase of the study. Subjects were tested at the start using one practice and one formal testing visit. Testing was repeated at the end of the statin/CoQ10 and statin/placebo portions of the study in one visit. Handgrip strength was measured using a handgrip dynamometer. Elbow flexor and knee extensor isometric and isokinetic force was measured using the Biodex System 3 isokinetic dynamometer (Biodex Medical, Shirley, New York). All measurements were taken on the dominant hand side of the body with measurements performed as described [11] .
Measurement of Aerobic Exercise Performance.VO2max and the ventilatory threshold were measured at the beginning of the CoQ10 section and after each treatment phase using a breath-bybreath gas analysis and a Parvomedics system (Parvomedics, Sandy, UT) during a modified Astrand exercise protocol.
Medication Compliance Assessment. Subjects were instructed to take three study pills (1 simvastatin and either 2 CoQ10 or 2 placebo tablets) daily. Subjects were queried regarding missed pills and problems taking medications during weekly phone calls during both the confirmation trial and CoQ10 portion of the study. Subjects returned unused pills after each portion of the study.
Statistical Analyses. Sample size was based on an expected 20% between-group difference in pain [6, 7] . This yielded a sample size of 40 subjects on CoQ10 and placebo to reject the null hypothesis and to detect possible interactions with gender, with power 0.9, and a type I error of 0.05. We aimed to identify 100 confirmed myalgics from the confirmation trial to assign 50 each to the CoQ10 and placebo arms of the trial. We estimated that 75% of recruited subjects would qualify as having confirmed statin myalgia. Consequently, we sought to recruit 135 myalgic subjects to enter the confirmation lead trial, which would yield approximately 100 subjects with confirmed myalgia to be randomly assigned to either the COQ10 or placebo groups. The confirmation trial yielded fewer confirmed myalgics than anticipated. Therefore, we added a crossover phase to the CoQ10 treatment study, where confirmed myalgics were treated with both CoQ10 and placebo. This permitted within-subjects comparisons and reduced the sample size needed to detect a treatment effect.
Standard diagnostics were performed to ensure that basic statistical assumptions, including variance homogeneity, normality, and the absence of outliers, were met prior to data analyses.
Resultant statistical analyses on the outcome were conducted with a linear mixed-effects model that accounts for the correlation among repeated measurements on an individual. In this repeated measures cross-over design there were two within subject factors (drug treatment and time). We examined the influence of other potential variables of interest (baseline serum CoQ10 levels, changes in serum CoQ10 levels, ethnicity, body mass index) as either between-subject factors with interaction terms in the Analysis of Variance (ANOVA) model or as continuous predictors in an Analysis of Covariance (ANCOVA) model. Comparisons of responses in the cross-over portion of the study were conducted with a paired-t test of individual change scores on CoQ10 vs. placebo.
Results
Data were collected from October 2009e2012. Characteristics of subjects who completed both the placebo and simvastatin phase of the confirmation trial and either did (n ¼ 43) or did not (n ¼ 77) develop myalgia are presented in Table 1 . Subjects with confirmed myalgia who subsequently entered the treatment phase of the study had a higher BMI and greater CK levels at study entry. Patients who received statin therapy first in the confirmation trial were also more likely to develop myalgia (28 of 64) than those who received it second (15 of 56) (c 2 ¼ 3.7; p ¼ 0.05). In addition, while there were no differences in the characteristics of myalgia between groups (i.e., involved muscle groups, location), time to pain onset after starting simvastatin was significantly shorter in the confirmed myalgics relative to the subset of non-myalgic patients who experienced pain on simvastatin (1.7 ± 1.4 weeks vs. 3.0 ± 1.8 weeks; p < 0.01). Subjects receiving simvastatin with CoQ10 in the treatment phase increased total serum CoQ10 from 1.3 ± 0.4 to 5.2 ± 2.3 mcg/ mL whereas serum CoQ10 decreased in the simvastatin and placebo group from 1.3 ± 0.3 to 0.8 ± 0.2; p < 0.05 for comparison. In addition, in the subjects who returned for the cross-over phase of the CoQ10 trial, serum CoQ10 also increased with CoQ10 treatment (D 4.3 ± 2.0) and decreased with placebo treatment (D À0.5 ± 0.3; p < 0.01). LDL-C decreased similarly in both the CoQ10 or placebo plus statin groups (Tables 2 and 3 ).
The Pain Severity Score (PSS) and the Pain Intensity Score (PIS) increased with statin therapy (both p < 0.01) in both groups with no difference between CoQ10 and placebo treatment (p ¼ 0.53 for PSS and 0.56 for PIS for drug*time interaction). There were no changes in CK, muscle strength or aerobic performance with statin treatment in the CoQ10 and placebo treatment groups ( Table 2 ). The number of subjects reporting muscle pain at the end of treatment was marginally higher with CoQ10 treatment:14 of 20 (70.0%) vs 7 In the 24 subjects who participated in both arms of the CoQ10 or placebo phase, there were no differences in muscle and exercise performance, PSS and PIS, or pain at the end of statin treatment. There was also no difference in the number of subjects reporting muscle pain (17 of 
Discussion
Seven previous trials have evaluated the impact of coenzyme Q10 on muscle symptoms with four showing benefit and three showing no effect [6,7,12e16] . In addition, a recent meta-analysis of 5 of these studies with 253 participants found no significant effect of CoQ10 on muscle pain, (observing only a trend toward a decrease [17] ). The discrepancy between trials is not readily explained by the dose of CoQ10 used, the patient population studied, the statins administered, or the duration of therapy. We designed a trial specifically for high interval validity to explore this area and generated some important findings. Unlike previous trials, subjects who reported previous statin myalgia in our trial were first put through a confirmation phase where they were randomized to simvastatin 20 mg daily or placebo for 8 weeks and then crossed over to alternative therapy. Only 35.8% of patients experienced myalgia on simvastatin and did not experience it on placebo, what we term true or confirmed statin myalgia, and 17.5% of patients had no symptoms on simvastatin or placebo which could have been because the dose we selected was too low. However, 29.2% experienced pain on placebo but not on simvastatin and 17.5% experienced pain on both simvastatin and placebo during the confirmation phase. Therefore, it is likely that only 30e50% of subjects in previous CoQ10 studies actually had muscle pain due to statins and not from other causes. This plus the small sample sizes of these trials may have contributed to the varying results.
We only allowed subjects with confirmed statin myalgia to enter the intervention phase where they were again placed on simvastatin 20 mg daily (in order to exactly replicate the regimen that evoked myalgia in the lead-in phase) plus either CoQ10 or placebo for 8 weeks. CoQ10 supplementation had no effect on the incidence and severity of myalgia, time to onset of pain, muscle strength, or aerobic performance. These negative results occurred in the presence of elevated serum concentrations of CoQ10 in the treatment group (as opposed to reductions in the placebo group) and no group differences in the LDL-lowering effects of simvastatin. This demonstrates that CoQ10 does not reduce the lipid-lowering effect of statins but also does not reduce muscle symptoms.
We did not detect any reductions in muscle strength or aerobic performance when statins were combined with placebo in our confirmed statin myalgics. There are observational reports of decreased muscle strength and aerobic performance in statin myalgics [2, 18] , but few rigorous assessments of muscle strength and aerobic performance with statins in general and particularly in patients with confirmed myalgia. We examined muscle strength and exercise performance in subjects meeting a study definition of statin myalgia in our previous Effect of STatins On Skeletal Muscle Performance or STOMP trial which randomized healthy, statinnaïve patients to atorvastatin 80 mg daily or placebo for 6 months [3] . There were no significant differences in the two groups in muscle and exercise performance in STOMP. The statin plus placebo intervention phase of our present study examined subjects with confirmed statin myalgia and also failed to find reductions in muscle strength, resting and aerobic performance.
We were surprised by the low number of subjects with a history of statin myalgia who tested positive with our confirmation process, although a recent small study using an n-of-1 double-blind crossover method of statin vs. placebo administration to confirm statin myalgia in individual patients with muscle complaints also found no difference between muscle pain and myalgia scores in both treatment conditions [19] . Collectively, these findings emphasize the need to develop more objective tools to diagnose statin myalgia for both clinical and research use. While there was no discernable pattern of location or type of muscle pain in subjects with or without confirmed myalgia that would distinguish the groups clinically, the time to pain onset in patients with confirmed statin myalgia was significantly shorter (1.7 ± 1.4 weeks vs. 3.0 ± 1.8 weeks) than in those patients who did not test positive for myalgia but still experienced muscle pain on simvastatin (i.e., the subset of patients who experienced muscle pain on both simvastatin and placebo). We have reported similar findings regarding a shorter time to pain onset with statin therapy in myagics on atorvastatin vs. placebo [3] and thus the time course of pain could be used clinically to more accurately assess reports of statin myalgia. We also identified three additional factors that were different in those with confirmed statin myalgia. Subjects with confirmed myalgia had higher baseline CK values which suggests that some pre-statin muscle process predisposes these patients to statin myalgia. This is to our knowledge the first time that differences in CK have been Table 2 Treatment responses to coEnzyme Q10 vs. placebo in confirmed myalgic subjects.
Age (yrs) 58 ± 10 e 60 ± 10 e LDL-C (mg/dL) 145 ± 31 99 ± 21* 158 ± 33 103 ± 19* CK (U/ * denotes a significant change from baseline within a group at p < 0.05. There were no significant between-group differences in any variable.
a All knee and elbow strength variables are reported as average peak torque in Newton-meters.
identified as a possible marker of statin myalgia. Baseline BMI was also higher in those with confirmed statin myalgia. Subjects with confirmed statin myalgia were also more likely to have received statin during the first phase of the confirmation trial. It is possible that muscle discomfort during subsequent placebo treatment could be compared with earlier, possibly more severe, complaints during statin treatment and permitted subjects to differentiate correctly between statin-associated and non-specific muscle complaints. None of these factors could be used clinically to predict which individuals will or will not develop confirmed statin myalgia.
There are limitations to the study. We chose to use simvastatin because it is widely used, may evoke more adverse muscle effects than other statins at similar LDL-lowering doses [20, 21] , and was generically available at study onset. We chose 20 mg daily because we were concerned that with higher doses, patients would not participate or would not tolerate treatment long enough to detect beneficial effects of CoQ10 during the intervention phase. Higher simvastatin doses may have increased the number of patients developing myalgia with statins in the confirmation phase thereby increasing the sample for the intervention phase. Limiting treatment duration in the confirmation and treatment phrases to 8 weeks of therapy may have limited our ability to detect confirmed statin myalgic patients. We chose 600 mg/d of the reduced form of CoQ10, ubiquinol, which is more effectively absorbed by older adults because previous studies using CoQ10 doses between 100 and 200 mg/d of CoQ10 have been criticized for using too low a dose [6, 7] . Neurocognitive studies have used 1200e2400 mg/d of CoQ10 doses [22] , but 600 mg/d increased CoQ10 serum concentrations above baseline and prevented the reduction in CoQ10 concentrations with statin therapy observed in the placebo group. We did not, however, measure intramuscular CoQ10 concentrations so it is possible that we did not elevate muscle CoQ10, but oral administration of CoQ10 in animal models increases both plasma and skeletal muscle CoQ10 concentrations [23, 24] , suggesting that the absence of a CoQ10 effect in the current study is not due to failure of CoQ10 to enter the muscle. Finally, we were only able to collect complete data on 38 patients into the initial study design and 24 patients into the cross-over treatment design because we were able to confirm statin myalgia in only 36% of recruited subjects with a history of myalgia. Consequently, we did not randomize 50 subjects to each treatment group as planned and had to alter our design to include a subject cross-over in the treatment phase. Nevertheless, the present study is one of the largest to test CoQ10 treatment in statin myalgia and the only study using only confirmed statin myalgic subjects. Furthermore, muscle pain and myalgia increased marginally in the CoQ10 group, and we estimate from our results that approximately 360 subjects per group would have been required to prove that CoQ10 does indeed reduce statin myalgia.
Conclusions
CoQ10 supplementation is widely prescribed for statinassociated muscle side effects but previous trials were small and yielded varying results. We used a verification lead-in phase to confirm statin myalgia and entered only those subjects who had myalgia on simvastatin but not on placebo into the CoQ10 or placebo intervention phase. Only a third of patients with a history of statin myalgia had myalgia with simvastatin 20 mg but not with placebo during the confirmation protocol demonstrating the difficulty of diagnosing and evaluating possible therapies in statin myalgia. Our results demonstrate that CoQ10 does not reduce statin myalgia in subjects with confirmed statin myalgia.
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Simvastatin þ CoQ10
Simvastatin þ placebo a All knee and elbow strength variables are reported as average peak torque in Newton-Meters. * denotes a significant difference between groups at p < 0.05.
